CN113924087A - 血清素4受体激动剂对抗应激的预防功效 - Google Patents

血清素4受体激动剂对抗应激的预防功效 Download PDF

Info

Publication number
CN113924087A
CN113924087A CN202080042252.4A CN202080042252A CN113924087A CN 113924087 A CN113924087 A CN 113924087A CN 202080042252 A CN202080042252 A CN 202080042252A CN 113924087 A CN113924087 A CN 113924087A
Authority
CN
China
Prior art keywords
stress
mice
administered
subject
induced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080042252.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·A·丹尼
A·M·加德尔
D·J·大卫
I·门德斯-大卫
C·费伊
B·K·陈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French National Institute Of Health And Medicine
Mental Health Research Foundation
Paris Thackeray, University of
Columbia University in the City of New York
Original Assignee
French National Institute Of Health And Medicine
Mental Health Research Foundation
Paris Thackeray, University of
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French National Institute Of Health And Medicine, Mental Health Research Foundation, Paris Thackeray, University of, Columbia University in the City of New York filed Critical French National Institute Of Health And Medicine
Publication of CN113924087A publication Critical patent/CN113924087A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080042252.4A 2019-04-09 2020-04-08 血清素4受体激动剂对抗应激的预防功效 Pending CN113924087A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962831517P 2019-04-09 2019-04-09
US62/831,517 2019-04-09
US201962857075P 2019-06-04 2019-06-04
US62/857,075 2019-06-04
US201962910859P 2019-10-04 2019-10-04
US62/910,859 2019-10-04
PCT/US2020/027321 WO2020210393A1 (en) 2019-04-09 2020-04-08 Prophylactic efficacy of serotonin 4 receptor agonists against stress

Publications (1)

Publication Number Publication Date
CN113924087A true CN113924087A (zh) 2022-01-11

Family

ID=72750568

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080042252.4A Pending CN113924087A (zh) 2019-04-09 2020-04-08 血清素4受体激动剂对抗应激的预防功效

Country Status (8)

Country Link
US (1) US20220031684A1 (https=)
EP (1) EP3952852A4 (https=)
JP (1) JP7683882B2 (https=)
CN (1) CN113924087A (https=)
AU (1) AU2020271839B2 (https=)
CA (1) CA3136328A1 (https=)
MX (1) MX2021012394A (https=)
WO (1) WO2020210393A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118105081A (zh) * 2024-03-04 2024-05-31 天津大学 一种情绪状态与神经电生理状态调节装置、验证系统及方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7821116B2 (ja) * 2020-04-07 2026-02-26 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
EP4577305A2 (en) * 2022-08-25 2025-07-02 1/1The Trustees Of Columbia University In The City Of New York Compositions and methods for the treatment of alzheimer's disease and other neurogenerative disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US20180325844A1 (en) * 2015-11-17 2018-11-15 The Trusttees of Columbia University in the City of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
EP2640398A4 (en) 2010-11-18 2014-05-14 White Mountain Pharma Inc METHOD FOR TREATING CHRONIC OR BZW. NON-RELIABLE PAIN AND / OR INCREASE OF PATIENT PAIN THRESHOLD AND PHARMACEUTICAL COMPOSITION FOR USE THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170899A1 (en) * 2004-09-14 2009-07-02 Guy Debonnel Stimulators of 5-HT4 receptors and uses thereof
US20180325844A1 (en) * 2015-11-17 2018-11-15 The Trusttees of Columbia University in the City of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
C.FAYE等: "Rapid anxiolytic effects of a serotonin type 4 receptor agonist involve prefrontal cortex/brainstem neural circuit recruitment", 《EUROPEAN NEUROPSYCHOPHARMACOLOGY》, vol. 28, pages 21 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118105081A (zh) * 2024-03-04 2024-05-31 天津大学 一种情绪状态与神经电生理状态调节装置、验证系统及方法

Also Published As

Publication number Publication date
JP7683882B2 (ja) 2025-05-27
CA3136328A1 (en) 2020-10-15
AU2020271839B2 (en) 2025-04-24
US20220031684A1 (en) 2022-02-03
EP3952852A1 (en) 2022-02-16
MX2021012394A (es) 2022-01-19
WO2020210393A1 (en) 2020-10-15
EP3952852A4 (en) 2023-01-04
JP2022527865A (ja) 2022-06-06
AU2020271839A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
EP3606525B1 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
US12239614B2 (en) Pharmacological prophylactics against stress-induced affective disorders in females
JP7821116B2 (ja) ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法
US20220031684A1 (en) Prophylactic efficacy of serotonin 4 receptor agonists against stress
JP2021526507A (ja) 発作により誘発される突然死を処置するための組成物および方法
US20220071932A1 (en) Compositions and Methods Against Stress-Induced Affective Disorders and Their Associated Symptoms
US20200054622A1 (en) Methods and Compositions for Treating Aging-Associated Impairments Using CCR3-Inhibitors
CN101873799A (zh) 用于治疗创伤后应激障碍的4-羟基-4-甲基-哌啶-1-羧酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺
CA2852978C (en) Methods for the prevention and/or treatment of memory impairment
JP2024153742A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法および組成物
US20200316087A1 (en) Novel combination therapy for anxiety disorders, epilepsy, and pain
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
WO2023215344A2 (en) Compositions and methods for treating cluster-tic syndrome
WO2023215342A1 (en) Compositions and methods for treating trigeminal neuralgia
WO2023215338A1 (en) Compositions and methods for treating cluster headache
EA041892B1 (ru) Способы и композиции для лечения ассоциированных со старением нарушений с применением ccr3-ингибиторов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220111